Apellis Pharmaceuticals Inc Revenue Growth Rates (APLS), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Apellis Pharmaceuticals Inc   (NASDAQ: APLS)
 

APLS's Revenue Growth by Quarter and Year

Apellis Pharmaceuticals Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

APLS Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June -
1st Quarter March 268.30
FY 268.30

APLSs Annual Revenue
Apellis Pharmaceuticals Inc 's Revenue in the fiscal year 2025 $ 1,003.78 millions
Apellis Pharmaceuticals Inc 's Revenue in the fiscal year 2024 $ 781.37 millions
Apellis Pharmaceuticals Inc 's Revenue in the fiscal year 2023 $ 396.59 millions
Apellis Pharmaceuticals Inc 's Revenue in the fiscal year 2022 $ 75.42 millions
Apellis Pharmaceuticals Inc 's Revenue in the fiscal year 2021 $ 66.56 millions




APLS Revenue first quarter 2026 Y/Y Growth Comment
Apellis Pharmaceuticals Inc reported Revenue surge of 60.85% year on year in the first quarter 2026, to $ 268.30 millions, this is lower than Apellis Pharmaceuticals Inc 's recent average Revenue surge of 321.04%.

Looking into first quarter 2026 results within Major Pharmaceutical Preparations industry 50 other companies have achieved higher Revenue growth. While Apellis Pharmaceuticals Inc ' s Revenue jump of 60.85% ranks overall at the positon no. 395 in the first quarter 2026.


APLS Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - -5.94 % 45.19 % 545.98 %
3rd Quarter September - 132.98 % 78.29 % 400.45 %
2nd Quarter June - -10.62 % 110.27 % 481.92 %
1st Quarter March 60.85 % -3.21 % 284.24 % 211.89 %
FY   - 28.46 % 97.02 % -

Financial Statements
Apellis Pharmaceuticals Inc 's first quarter 2026 Revenue $ 268.30 millions APLS's Income Statement
Apellis Pharmaceuticals Inc 's first quarter 2025 Revenue $ 166.80 millions Quarterly APLS's Income Statement


APLS Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - -56.41 % 7.98 % 32.59 %
3rd Quarter September - 156.92 % -1.43 % 16.25 %
2nd Quarter June - 7.01 % 15.88 % 111.75 %
1st Quarter March 34.21 % -21.52 % 17.73 % 97.93 %
FY (Year on Year)   - 28.46 % 97.02 % -


Back to APLS Growth rate Comparisons >> Back to APLS Growth rate Comparisons >>


Revenue first quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #51
Healthcare Sector #102
Overall #395

Revenue Y/Y Growth Statistics
High Average Low
2519.9 % 321.04 % -75.88 %
(Dec 31 2023)   (Jun 30 2025)
Revenue first quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #51
Healthcare Sector #102
Overall #395
Revenue Y/Y Growth Statistics
High Average Low
2519.9 % 321.04 % -75.88 %
(Dec 31 2023)   (Jun 30 2025)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Apellis Pharmaceuticals Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
38599.69 % 1936.56 % -100 %
(Dec 31 2020)  


APLS's I. Quarter Q/Q Revenue Comment
Apellis Pharmaceuticals Inc achieved in the I. Quarter 2026 below company average Revenue jump of 34.21% quarter on quarter, to $ 268.30 millions.

I. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -21.52% in the I. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 17 other companies have achieved higher Revenue quarter on quarter growth. While Apellis Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 168.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #18
Healthcare Sector #38
Overall #168
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #18
Healthcare Sector #38
Overall #168
Revenue Q/Q Growth Statistics
High Average Low
38599.69 % 1936.56 % -100 %
(Dec 31 2020)  


APLS's I. Quarter Q/Q Revenue Comment
Apellis Pharmaceuticals Inc achieved in the I. Quarter 2026 below company average Revenue jump of 34.21% quarter on quarter, to $ 268.30 millions.

I. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the -21.52% in the I. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 17 other companies have achieved higher Revenue quarter on quarter growth. While Apellis Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 168.


Apellis Pharmaceuticals Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)		 12 Months Ending
(Mar 31 2025)
Cumulative Revenue 12 Months Ending $ 1,105.28 $ 1,003.78 $ 1,016.40 $ 754.65 $ 775.84
Y / Y Revenue Growth (TTM) 42.46 % 28.46 % 42.11 % 20.02 % 48.04 %
Year on Year Revenue Growth Overall Ranking # 178 # 36 # 37 # 8 # 19
Seqeuential Revenue Change (TTM) 10.11 % -1.24 % 34.68 % -2.73 % -0.71 %
Seq. Revenue Growth (TTM) Overall Ranking # 1918 # 758 # 620 # 117 # 274


Cumulative Revenue growth Comment
Although Apellis Pharmaceuticals Inc 's Annual Revenue growth year on year were below company's average 135.76% , Revenue announced in the Mar 31 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 42.46% year on year, from 28.46% in Dec 31 2025.

In the Healthcare sector 55 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 36 to 178.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 93
Healthcare Sector # 56
Overall # 178

Revenue TTM Y/Y Growth Statistics
High Average Low
425.83 %
 135.76 %
20.02 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 93
Sector # 268
S&P 500 # 1918
Cumulative Revenue growth Comment
Although Apellis Pharmaceuticals Inc 's Annual Revenue growth year on year were below company's average 135.76% , Revenue announced in the Mar 31 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 42.46% year on year, from 28.46% in Dec 31 2025.

In the Healthcare sector 55 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 36 to 178.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 93
Healthcare Sector # 56
Overall # 178

Revenue TTM Y/Y Growth Statistics
High Average Low
425.83 %
135.76 %
20.02 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 93
Sector # 268
S&P 500 # 1918




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
APLS's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Mar 31 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2026
Phathom Pharmaceuticals Inc 104.43%$ 104.429 millions
Profound Medical Corp 103.62%$ 103.625 millions
Qt Imaging Holdings Inc exact Name Of Registrant As Specified In Its Charter _______________________102.69%$ 102.686 millions
Vivos Therapeutics Inc 101.63%$ 101.634 millions
Protagonist Therapeutics inc 99.03%$ 99.033 millions
Alnylam Pharmaceuticals Inc 96.43%$ 96.432 millions
Abcellera Biologics Inc 96.34%$ 96.340 millions
Viridian Therapeutics Inc 95.83%$ 95.833 millions
Alamar Biosciences Inc 94.46%$ 94.462 millions
Bioage Labs Inc 91.04%$ 91.041 millions
Tenon Medical Inc 89.94%$ 89.945 millions
Vaxart Inc 87.90%$ 87.905 millions
Cannapharmarx Inc 87.12%$ 87.124 millions
Ionis Pharmaceuticals Inc 86.98%$ 86.982 millions
Picard Medical Inc 85.48%$ 85.484 millions
Therapeuticsmd Inc 84.22%$ 84.224 millions
Rhythm Pharmaceuticals Inc 83.81%$ 83.806 millions
Billiontoone Inc 83.33%$ 83.329 millions
Upstream Bio Inc 82.69%$ 82.686 millions
Neuraxis Inc 79.52%$ 79.520 millions
Fennec Pharmaceuticals Inc 72.64%$ 72.643 millions
Scilex Holding Company72.12%$ 72.122 millions
Gossamer Bio Inc 71.45%$ 71.453 millions
Innovative Eyewear Inc 70.20%$ 70.200 millions
Tg Therapeutics Inc 69.56%$ 69.556 millions
Seastar Medical Holding Corp68.94%$ 68.942 millions
Crispr Therapeutics Ag68.55%$ 68.555 millions
Bridgebio Pharma Inc 66.78%$ 66.775 millions
Aquestive Therapeutics Inc 65.67%$ 65.665 millions
Beyond Air Inc 65.54%$ 65.538 millions


About Apellis Pharmaceuticals Inc Revenue Growth Rates (APLS), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Apellis Pharmaceuticals Inc (CIK 1492422).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001492422-26-000108
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Apellis Pharmaceuticals Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.